EPR Properties vs IQVIA Holdings Inc. Common Stock — how do they compare? EPR Properties trades at $54.41 (market cap $4.17B), while IQVIA Holdings Inc. Common Stock trades at $258.85 (market cap $42.61B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 10.2× EPR Properties's market cap, and EPR Properties pays a 6.84% dividend while IQVIA Holdings Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 45 Days and IQVIA Holdings Inc. Common Stock for 0 Days on average.
| EPR | IQV | |
|---|---|---|
Market Cap | $4.17B | $42.61B |
Volume | 992,716 | 988,398 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $275.02 |
52-Week Low | $48.71 | $156.66 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $7.68B | $56.77B |
Dividend Yield | 6.84% | — |
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $54.08, down 2.15% today, with a bearish technical signal and oversold RSI suggesting potential reversal. The REIT maintains strong fundamentals with 91.41% gross margins and consistent dividend payments, though recent earnings showed a Q1 miss. Analyst consensus remains positive with a $65.50 price target, representing 21% upside from current levels.
EPR offers attractive income potential with a 6.5% dividend yield and diversified real estate portfolio, but faces headwinds from rising interest rates and mixed earnings performance. The stock's current valuation at 17.44 P/E appears reasonable, though technical weakness and negative cash flow projections for 2026 warrant caution for near-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →